Adagio Medical Holdings issued 4,978,869 shares of common stock upon the conversion of $776,111 in aggregate principal amount of its 13% Senior Secured Convertible Notes. This transaction occurred between September 25 and October 1, 2026, following an Alternate Conversion Election that lowered the conversion price to rates ranging from $0.1265 to $0.1618 per share. The issuance was exempt from registration under Section 3(a)(9) of the Securities Act as it involved an exchange with existing noteholders without additional consideration. Adagio Medical Holdings operates in the medical device industry, focusing on minimally invasive treatments for pelvic organ prolapse.
